IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 340
EU - Europa 156
NA - Nord America 85
AF - Africa 5
SA - Sud America 3
Totale 589
Salva come PNG Salva come JPEG
Nazione #
CN - Cina 219
SG - Singapore 116
US - Stati Uniti d'America 84
IT - Italia 61
RU - Federazione Russa 45
DE - Germania 19
FI - Finlandia 13
SE - Svezia 8
AR - Argentina 3
FR - Francia 3
RO - Romania 3
AT - Austria 2
JP - Giappone 2
NL - Olanda 2
UG - Uganda 2
ZA - Sudafrica 2
CA - Canada 1
KE - Kenya 1
KR - Corea 1
PK - Pakistan 1
UZ - Uzbekistan 1
Totale 589
Salva come PNG Salva come JPEG
Città #
Singapore 80
Shanghai 52
Boardman 40
Guangzhou 17
Moscow 15
Beijing 12
Milan 11
Shenzhen 11
Helsinki 9
Jiaxing 6
Comun Nuovo 5
Lawrence 5
Princeton 5
Xuzhou 5
Rome 4
Ashburn 3
Cipolletti 3
Cornaredo 3
Lappeenranta 3
Pisa 3
Quanzhou 3
Tulcea 3
Bari 2
Bologna 2
Brescia 2
Costa de' Nobili 2
Dongyang 2
Hangzhou 2
Kampala 2
Kumamoto 2
Nuremberg 2
Pretoria 2
Rui'an 2
San Nicola Manfredi 2
Santa Clara 2
Verona 2
Wuhan 2
Amsterdam 1
Changsha 1
Clifton 1
Council Bluffs 1
Dalian 1
Düsseldorf 1
Espoo 1
Falkenstein 1
Frattamaggiore 1
Görwihl 1
Lahore 1
Los Angeles 1
Munich 1
Nairobi 1
Nanjing 1
Naples 1
Padova 1
Sanming 1
Tashkent 1
Turin 1
Verdellino 1
Vienna 1
Weitang 1
Wuxi 1
Wuyuan 1
Xi'an 1
Yiwu 1
Totale 355
Salva come PNG Salva come JPEG
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 34
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 20
PARP Inhibitors for Breast Cancer Treatment: A Review 15
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 15
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 13
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 13
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 13
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 12
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 12
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 12
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 12
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 12
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 12
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 12
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 12
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 11
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 11
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 11
Spatial predictors of immunotherapy response in triple-negative breast cancer 11
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 11
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 11
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 11
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 10
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 10
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 10
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 10
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 10
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 9
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 9
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 9
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 9
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer? 9
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 9
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 9
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 9
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 9
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 8
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 8
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 8
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 8
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 8
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 8
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 8
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 8
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief 7
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 7
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 7
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 7
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 7
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 7
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 7
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 7
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 7
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab 7
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 7
An unmet need: tailoring extended adjuvant endocrine therapy. 7
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 7
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 7
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 7
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 7
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 7
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 6
Is trastuzumab as a single agent obsolete in early breast cancer? No 6
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 6
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 6
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. 6
Treatment options in hormone-refractory metastatic prostate carcinoma. 6
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer 6
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients 6
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 6
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 6
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 6
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 6
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. 6
HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry? 5
OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. 5
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 5
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 5
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 5
RESEARCH-BASED PAM50 SUBTYPE PREDICTOR IDENTIFIES HIGHER RESPONSES AND IMPROVED SURVIVAL OUTCOMES IN HER2-POSITIVE BREAST CANCER IN THE NOAH STUDY 5
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. 5
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 5
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 5
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 5
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 5
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers 4
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 4
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 4
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 4
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 4
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 4
Immunological differences between primary and metastatic breast cancer 4
The immune system and response to HER2-targeted treatment in breast cancer. 4
Surrogate markers for targeted therapy-based treatment activity and efficacy. 3
Erratum: Accurate data processing improves the reliability of affymetrix gene expression profiles from FFPE samples (PLoS ONE (2014) 9:1 (e86511)) 3
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 3
Molecular heterogeneity of estrogen receptor-positive breast cancer explains variable and contradictory results of randomized adjuvant chemotherapy trials in breast cancer 3
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 3
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 2
Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis 2
Totale 794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 1 1 0 0 0 0 0
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024205 0 0 3 3 1 42 12 8 1 3 61 71
2024/2025568 239 82 15 97 135 0 0 0 0 0 0 0
Totale 801